

FOR IMMEDIATE
RELEASE
May 19, 2007

Contact: Sharon Terry
202-966-5557 x201
sterry@geneticalliance.org

**Sharon Terry receives Award for Patient Service
at the University of North Carolina at Chapel Hill**

On May 19, Sharon Terry, MA, president and CEO of Genetic Alliance, was honored with the Institute for Pharmacogenomics and Individualized Therapy (IPIT) at the University of North Carolina at Chapel Hill Award for Patient Service. This award is given to an individual who has made significant contributions to empowering patients and who champion a focus on patient in the advancement of individualized therapy.

"The completion of the Human Genome Project brought the promise of new tools for choosing the safest and most beneficial medicines for patients," said Howard McLeod, director of the UNC institute. "But realizing these tools requires great dedication and leadership by experts from diverse areas of health sciences, leaders such as Sharon Terry."

"Scientific discovery does not automatically become clinically useful," McLeod said. "It takes extraordinary effort to convert an idea into better patient care."

"I am immensely honored to be given this first patient award. The UNC Institute for Pharmacogenomics and Individualized Therapy is sharply focused on the patient, bringing together researchers and clinicians across the University to create personalized therapies. Like us, they ask, what matters for the patient? Everything they do is through that lens. I am proud to stand as an award recipient with these dedicated professionals."

Also honored were: Janet Woodcock, MD, chief medical officer of the Food and Drug Administration, was named the recipient of the IPIT Award for Clinical Service. Her award honors a person who has made significant direct contributions to the advancement of individualized therapy in clinical practice.

Larry Lesko, PhD, director of the FDA Office of Clinical Pharmacology and Biopharmaceutics, received the IPIT Award for Public Service. His award honors a person who has made a significant impact on the advancement of individualized therapy across society.